NCT07588152RecruitingPhase 4
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 8 May 2026
- Start date
- 5 Jun 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Indiana University
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07588152
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 50
- From 5 Jun 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Corneal scarring or active corneal disease that would interfere with imaging
- Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion
Other
- Known intolerance to netarsudil ophthalmic solution
- Inability to tolerate gonioscopy procedures
- Females of childbearing potential who are not using effective contraception or are not sterile
Who the study is looking for
- Adults aged 18 years or older
- Diagnosis of ocular hypertension or open-angle glaucoma
- Eye examination within the past year
- For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma
- Best-corrected visual acuity of 20/100 or better
- Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)
- Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Indiana Universtiy School of Optometry Coordinator of this site? Confirm its status | Bloomington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.